Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

and Turkish ambassador Burhan Kuroglu. The Foreign Ministry said that the project will be implemented under a build-operate-transfer model that will see the private companies build and operate the ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...

Every Wednesday and Friday, TechNode’s Briefing newsletter delivers a roundup of the most important news in China tech, straight to your inbox. Sign up At its Tech World 2025 event in Shanghai on ...

Today's court listings are published as part of News Corporation's commitment to public interest journalism and are compiled from information made publicly available by the courts in each State ...

Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, ...

ABSTRACT: Logging is widely cited as a source of forest degradation, due to the many irregularities in this sector of activity that cause timber and monetary losses. This study aimed to determine the ...

A NOTE ABOUT RELEVANT ADVERTISING: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our ...

0197761 National Institutes of Health. Somatotypes—MeSH. Britannica. William Sheldon. Ciftci R, Kurtoglu A. Examination of the Effect of Somatotype Profiles on Athletic Performance Indicators in ...

One member of the group, Melanie Kurtoglu, posted dash cam footage that depicts a driver weaving in and out of traffic on Lee Boulevard. Kurtoglu wrote “There is absolutely no reason to be ...

Metin Kurtoglu, the Chief Technology Officer of Cartesian Therapeutics, Inc. (NASDAQ:RNAC), a $442 million market cap biotech company currently trading at $17.16, recently sold shares of the ...